The 19 most recent market catalysts affecting $PODD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179
Canaccord Genuity analyst William Plovanic maintained a 'Buy' rating on Insulet (PODD) but drastically lowered the price target from $249 to $179. This action indicates that while …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
Leerink Partners Downgrades Insulet to Market Perform, Lowers Price Target to $145
Leerink Partners analyst Mike Kratky downgraded Insulet (PODD) from Outperform to Market Perform and slashed the price target from $247 to $145. This significant revision reflects …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Neutral on Insulet, Lowers Price Target to $150
UBS analyst Patrick Wood lowered Insulet's (PODD) price target from $174 to $150, while keeping a 'Neutral' rating. This adjustment reflects a revised valuation by a prominent anal…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 65
RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $160
RBC Capital's analyst Shagun Singh maintained an 'Outperform' rating on Insulet but drastically lowered the price target from $245 to $160. This action is significant because while…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
Bernstein Maintains Outperform on Insulet, Lowers Price Target to $175
Bernstein analyst Lee Hambright maintained an 'Outperform' rating on Insulet (PODD), signaling a continued belief in the company's long-term prospects. However, the price target wa…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 65
Benchmark Maintains Buy on Insulet, Lowers Price Target to $185
Benchmark analyst Bruce D. Jackson maintained a 'Buy' rating on Insulet (PODD) but lowered the price target from $250 to $185. This action is significant because a substantial redu…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 65
Stifel Maintains Buy on Insulet, Lowers Price Target to $180
Stifel analyst Jonathan Block maintained a 'Buy' rating on Insulet (PODD) but lowered the price target from $225 to $180. This action indicates that while the analyst still sees lo…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
These Analysts Slash Their Forecasts On Insulet After Q2 Results
Insulet (PODD) delivered a mixed earnings report, with Q2 results beating estimates but forward guidance falling short. The company lowered its full-year 2026 revenue outlook and p…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
JP Morgan Downgrades Insulet to Neutral, Lowers Price Target to $152
JP Morgan analyst Robbie Marcus downgraded Insulet (PODD) from Overweight to Neutral and slashed the price target from $275 to $152. This significant revision reflects a more cauti…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
Truist Securities Downgrades Insulet to Hold, Lowers Price Target to $153
Truist Securities analyst Richard Newitter downgraded Insulet (PODD) from a 'Buy' to a 'Hold' rating and lowered the price target from $210 to $153. This significant reduction in b…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 85
Omnipod Sales Soar, But Insulet's Outlook Cut Sparks Stock Selloff
Insulet (PODD) delivered a strong second quarter, exceeding analyst estimates for both earnings and revenue, primarily due to robust Omnipod sales growth. However, the positive Q2 …
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
Insulet shares are trading lower after the company reported Q2 financial results and cut its FY26 sales guidance. Also, the company issued Q3 sales guidance below estimates.
This headline represents a major corporate catalyst for Insulet (PODD). The combination of missed Q2 expectations, a reduced long-term sales forecast (FY26), and weak near-term gui…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.43 Est; Lowers FY2026 Sales Guidance from $3.277B-$3.331B to $3.250B-$3.304B vs $3.321B Est
Insulet (PODD) announced a mixed update to its FY2026 financial guidance. The company raised its adjusted EPS expectation to 'more than $6.46' from an estimated $6.43, indicating p…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Insulet Q2 Adj. EPS $1.66 Beats $1.45 Estimate, Sales $801.700M Beat $787.228M Estimate
Insulet (PODD) announced Q2 adjusted EPS of $1.66, significantly surpassing the $1.45 estimate, and sales of $801.7 million, beating the $787.228 million estimate. This strong perf…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 55
Insulet Corporation Partners With Calm To Provide Free Mindfulness Resources Addressing Anxiety And Burnout Among People Living With Diabetes
Insulet Corporation (PODD) has partnered with Calm to launch 'The Mind in Range Collection,' offering free mindfulness resources to individuals with diabetes. This initiative is si…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210
Truist Securities analyst Richard Newitter has maintained a 'Buy' rating on Insulet (PODD), signaling continued confidence in the company's long-term prospects. However, the slight…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $245
RBC Capital's decision to maintain an 'Outperform' rating on Insulet suggests that the analyst still sees strong long-term potential for the company. However, the reduction in the …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.